Lumexa Imaging Announces Fourth Quarter and Full Year 2025 Results, Reiterates Full Year 2026 Guidance
Rhea-AI Summary
Lumexa Imaging (Nasdaq: LMRI) reported preliminary, unaudited fourth-quarter and full-year 2025 results and reiterated 2026 guidance on March 26, 2026. Q4 revenue was $267.7 million, up 7.9% year-over-year, with Adjusted EBITDA of $63.8 million (23.8% margin). Full-year 2025 revenue was $1.023 billion and Adjusted EBITDA was $230.2 million. The company cut leverage from 5.5x to 3.5x and added ten facilities in 2025. 2026 guidance: revenue $1.045–1.097 billion and Adjusted EBITDA $234–242 million; Adjusted EPS $0.71–0.77.
Positive
- Revenue +7.8% to $1.023 billion in 2025
- Adjusted EBITDA +14.6% to $230.2 million in 2025
- Leverage reduced by 2.0 turns from 5.5x to 3.5x
- Opened 10 new facilities during 2025
Negative
- Net loss of $47.1 million for full-year 2025
- Q4 net loss of $28.7 million despite EBITDA growth
- 2026 guidance includes ~$7 million incremental public company costs
News Market Reaction – LMRI
In the Mar 26 session, LMRI declined 29.84%, reflecting a significant negative market reaction. Argus tracked a trough of -19.7% from its starting point during tracking. Our momentum scanner triggered 48 alerts that day, indicating elevated trading interest and price volatility. Trading volume was elevated at 2.2x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 17 | Investor conferences | Positive | +6.0% | Announced CEO and CFO participation in three March 2026 investor conferences. |
| Jan 28 | Leadership recognition | Positive | -2.8% | Dr. Kemp elected to RSNA Board, highlighting quality and patient-centered care focus. |
| Jan 08 | De novo expansion | Positive | +2.5% | Reported record nine de novo centers in 2025, expanding to 185+ centers in 13 states. |
| Jan 05 | JPM conference | Positive | +3.3% | Announced CEO and CFO participation at the 44th Annual J.P. Morgan Healthcare Conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news with generally positive tone has more often led to positive price reactions, with one notable divergence on a governance/recognition headline.
Over the past few months, Lumexa has focused on visibility and growth execution. In January 2026, it highlighted record de novo expansion and participation in the J.P. Morgan Healthcare Conference, both followed by moderate gains. Subsequent conference participation news in February 2026 also saw a strong positive move. A governance-focused update on RSNA board election produced a small decline. Today’s Q4 and full-year 2025 earnings and 2026 guidance fit into this ongoing growth and outreach narrative.
Key Terms
adjusted ebitda financial
adjusted eps financial
gaap financial
non-gaap financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
RALEIGH, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today announced certain financial results for the fourth quarter ended December 31, 2025, and reiterated full year 2026 guidance. The financial results included in this release pertaining to the fourth quarter and full year 2025 are preliminary, unaudited, and subject to final review and adjustment.
“The fourth quarter of 2025 marked a strong close to an important year for Lumexa Imaging, with continued momentum across the business,” said Caitlin Zulla, Chief Executive Officer of Lumexa Imaging. “Strong Adjusted EBITDA growth was driven by advanced imaging volumes, ramping new de novo centers, and our return in-network with a large payer in New Jersey. We strengthened our balance sheet, reducing leverage by two turns, and opened a record number of de novo centers during the year, setting the stage for future growth.”
Ms. Zulla continued, “Looking ahead, our 2026 outlook reflects continued growth and margin expansion, supported by durable demand tailwinds and the ongoing shift to outpatient care. With a focused strategy centered on same-center growth, geographic expansion, and advanced imaging, we believe Lumexa Imaging is well positioned to deliver sustained, profitable growth while expanding access to high-quality, lower-cost imaging for patients, providers, and payors.”
Fourth Quarter 2025 Highlights:
All comparisons are to the quarter ended December 31, 2024, unless otherwise noted
- Consolidated revenues of
$267.7 million , an increase of7.9% from$248.0 million - System-wide revenue growth of
10.6% - Same center advanced volume growth:
12.7% for consolidated and9.2% for system-wide - Net loss of
$28.7 million compared to$25.1 million - Adjusted EBITDA of
$63.8 million , an increase of18.6% from$53.7 million ; and a23.8% Adjusted EBITDA margin - Achieved a two-turn reduction in leverage from 5.5 times to 3.5 times, resulting in more than
$50 million in annual cash savings
2025 Full Year Highlights:
All comparisons are to the year ended December 31, 2024, unless otherwise noted
- Added ten new imaging facilities: Nine de novo centers (six wholly owned and three through joint ventures) and one acquired site
- Consolidated revenues of
$1.023 billion , an increase of7.8% from$948.9 million - System-wide revenue growth of
8.2% - Same center advanced volume growth:
8.0% for consolidated and7.1% for system-wide - Net loss of
$47.1 million compared to$94.1 million - Adjusted EBITDA of
$230.2 million , an increase of14.6% from$200.8 million ; and a22.5% Adjusted EBITDA margin
Outpatient Volumes:
| Consolidated | 2025 | 2024 | Increase YoY | 4Q25 | 4Q24 | Increase YoY | |||||
| Consolidated total procedures | 2,418,096 | 2,312,645 | 4.6 % | 627,293 | 569,734 | 10.1 % | |||||
| Consolidated advanced procedures | 728,304 | 675,697 | 7.8 % | 190,982 | 167,184 | 14.2 % | |||||
| % advanced procedures | 30.1 % | 29.2 % | 90bps | 30.4 % | 29.3 % | 110bps | |||||
| Consolidated same-center advanced volume growth | ------ | ------ | 8.0 % | ------ | ------ | 12.7 % | |||||
| System-wide | |||||||||||
| System-wide total procedures | 3,972,228 | 3,840,624 | 3.4 % | 1,027,590 | 962,520 | 6.8 % | |||||
| System-wide advanced procedures | 1,444,618 | 1,340,951 | 7.7 % | 379,527 | 341,859 | 11.0 % | |||||
| % advanced procedures | 36.4 % | 34.9 % | 145bps | 36.9 % | 35.5 % | 142bps | |||||
| System-wide same-center advanced volume growth | ------ | ------ | 7.1 % | ------ | ------ | 9.2 % | |||||
| Note: Advanced Procedures includes MRI and CT modalities. | |||||||||||
2026 Full Year Outlook:
The company is reiterating its outlook for the year ending December 31, 2026. Lumexa Imaging continues to expect:
- Consolidated revenues of
$1.045 t o$1.097 billion - Adjusted EBITDA of
$234 t o$242 million . This includes approximately$7 million of public company costs that were not incurred in 2025. (At the midpoint of guidance, the addition of these costs lowers Adjusted EBITDA growth for 2026 versus 2025 from7% to4%
The company is also providing guidance for Adjusted EPS of
The financial information above is preliminary and subject to Lumexa Imaging’s normal quarter and year-end accounting procedures and external audit by Lumexa Imaging’s independent registered public accounting firm. In addition, these preliminary unaudited results are not a comprehensive statement of Lumexa Imaging’s financial results for the year ended December 31, 2025, should not be viewed as a substitute for full, audited consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), and are not necessarily indicative of Lumexa Imaging’s results for any future period.
Lumexa Imaging Earnings Conference Call and Webcast
Lumexa Imaging will host a conference call to discuss its fourth quarter and full year 2025, as well as its 2026 outlook, on March 26, 2026 at 8:30 a.m. ET. Participants can register for the conference call at the following link: https://register-conf.media-server.com/register/BI5d8d23fe681d4694851e49a7f37188bd. The call can also be accessed via live audio webcast online at ir.lumexaimaging.com. A replay of the webcast will be available at the same link shortly after the completion of the call and will remain available for approximately one year.
Statement Regarding Use of Non-GAAP Financial Measures
This press release uses Adjusted EBITDA and Adjusted EPS, financial measures that are not calculated in accordance with GAAP. We use Adjusted EBITDA and Adjusted EPS, in conjunction with GAAP financial measures, as an integral part of managing our business and to, among other things: (i) monitor and evaluate the performance of our business operations and financial performance; (ii) facilitate internal comparisons of the historical operating performance of our business operations; (iii) review and assess the operating performance of our management team; and (iv) analyze and evaluate financial and strategic planning decisions regarding future operations and annual operating budgets. For a reconciliation of Adjusted EBITDA to the most directly comparable measure calculated in accordance with GAAP, please see below.
We have not reconciled our Adjusted EBITDA or Adjusted EPS guidance to their most directly comparable GAAP measures because we do not and are not able to provide guidance for those GAAP measures due to the uncertainty and potential variability of certain reconciling items, including transaction costs, severance and executive recruiting. Because such items cannot be provided without unreasonable efforts, we are unable to provide a reconciliation of our Adjusted EBITDA guidance to GAAP net loss. However, such items could have a significant impact on our future results.
About Lumexa Imaging
Lumexa Imaging is a nationwide provider of outpatient medical imaging. With over 5,000 team members and more than 188 outpatient imaging centers across 13 states, our team conducted approximately 4 million outpatient procedures system-wide in 2025. We are a partner of choice for health systems and radiologists, delivering best-in-class clinical excellence, operations, and state-of-the-art technology across our platform.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," or "will," or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this release include, but are not limited to, statements regarding our expectations regarding our financial position and operating performance, including our performance for the fourth quarter and full year 2025 and guidance for full year 2026 and our assumptions underlying such guidance; our ability to drive future growth and execute on our goals and strategies; and our expectations regarding our product innovation. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including but not limited to those risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Form S-1 and related Prospectus pursuant to Rule 424(b)(4) of Lumexa Imaging, each as filed with the Securities and Exchange Commission (SEC). The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligations to update any forward-looking statements, except as required by law.
Investor Contact
Sue Dooley
Lumexa Imaging
sue.dooley@Lumexaimaging.com
Media Contact
Melissa Weston
Lumexa Imaging
Melissa.Weston@LumexaImaging.com
| LUMEXA IMAGING HOLDINGS, INC. | ||||||||
| CONSOLIDATED BALANCE SHEETS | ||||||||
| DECEMBER 31, 2025 AND 2024 | ||||||||
| (IN THOUSANDS, EXCEPT FOR COMMON SHARES) | ||||||||
| (Preliminary and Unaudited) | ||||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Cash and cash equivalents | $ | 58,828 | $ | 26,131 | ||||
| Accounts receivable | 112,942 | 107,046 | ||||||
| Accounts receivable, related party | 18,893 | 23,308 | ||||||
| Other receivables | 19,015 | 5,644 | ||||||
| Prepaid expenses | 17,582 | 10,391 | ||||||
| Total current assets | 227,260 | 172,520 | ||||||
| Property and equipment, net of accumulated depreciation | 144,709 | 121,133 | ||||||
| Operating lease right-of-use assets | 76,555 | 80,792 | ||||||
| Investments in unconsolidated affiliates | 423,191 | 415,819 | ||||||
| Intangible assets, net of accumulated amortization | 41,335 | 47,788 | ||||||
| Goodwill | 807,554 | 807,554 | ||||||
| Other assets | 43,953 | 24,958 | ||||||
| TOTAL ASSETS | $ | 1,764,557 | $ | 1,670,564 | ||||
| LIABILITIES AND EQUITY | ||||||||
| Accounts payable | $ | 44,857 | $ | 29,889 | ||||
| Accrued expenses and other current liabilities | 95,561 | 108,454 | ||||||
| Accounts receivable pledging arrangement | 1,599 | - | ||||||
| Current portion of long-term debt | 13,112 | 16,001 | ||||||
| Current portion of finance lease liabilities | 11,552 | 5,509 | ||||||
| Current portion of operating lease liabilities | 12,513 | 13,807 | ||||||
| Total current liabilities | 179,194 | 173,660 | ||||||
| Long-term debt, less current maturities | 819,029 | 1,185,080 | ||||||
| Long-term finance lease liabilities, less current maturities | 33,262 | 16,120 | ||||||
| Long-term operating lease liabilities, less current maturities | 71,437 | 72,746 | ||||||
| Deferred income taxes | 40,772 | 32,696 | ||||||
| Other liabilities | 34,740 | 28,608 | ||||||
| Total liabilities | 1,178,434 | 1,508,910 | ||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| EQUITY: | ||||||||
| Common stock, | 96 | 70 | ||||||
| Additional paid-in-capital | 1,217,087 | 745,540 | ||||||
| Accumulated deficit | (631,060 | ) | (583,956 | ) | ||||
| Total equity | 586,123 | 161,654 | ||||||
| TOTAL LIABILITIES AND EQUITY | $ | 1,764,557 | $ | 1,670,564 | ||||
| LUMEXA IMAGING HOLDINGS, INC. | ||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||||||||||
| FOR THE YEARS AND QUARTER ENDED DECEMBER 31, 2025 AND 2024 | ||||||||||||||||
| (IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE DATA) | ||||||||||||||||
| (Preliminary and Unaudited) | ||||||||||||||||
| Year Ended December 31, | Quarter Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| REVENUES: | ||||||||||||||||
| Net patient service revenue | $ | 802,707 | $ | 746,850 | $ | 210,529 | $ | 189,829 | ||||||||
| Management fee and other revenue | 220,374 | 202,019 | 57,205 | 58,199 | ||||||||||||
| Total revenues | 1,023,081 | 948,869 | 267,734 | 248,028 | ||||||||||||
| OPERATING EXPENSES: | ||||||||||||||||
| Cost of operations, excluding depreciation and amortization | 865,516 | 852,606 | 225,618 | 226,456 | ||||||||||||
| General and administrative expenses | 90,453 | 70,361 | 37,191 | 20,120 | ||||||||||||
| Depreciation and amortization | 40,379 | 42,164 | 12,395 | 9,816 | ||||||||||||
| Loss on disposal of property and equipment | 968 | - | 491 | - | ||||||||||||
| Total operating expenses | 997,316 | 965,131 | 275,695 | 256,392 | ||||||||||||
| Equity in earnings of unconsolidated affiliates | 72,135 | 71,505 | 22,300 | 23,615 | ||||||||||||
| INCOME FROM OPERATIONS | 97,900 | 55,243 | 14,339 | 15,251 | ||||||||||||
| OTHER INCOME AND EXPENSES: | ||||||||||||||||
| Interest expense | 118,539 | 136,027 | 28,016 | 31,387 | ||||||||||||
| Loss on extinguishment of debt | 13,453 | 703 | 13,453 | - | ||||||||||||
| Other income | (1,873 | ) | - | (1,873 | ) | (110 | ) | |||||||||
| Gain on imaging center sold, related party | — | (2,294 | ) | — | — | |||||||||||
| Total other expenses | 130,119 | 134,436 | 39,596 | 31,277 | ||||||||||||
| LOSS BEFORE INCOME TAXES | (32,219 | ) | (79,193 | ) | (25,257 | ) | (16,026 | ) | ||||||||
| Income tax provision | 14,885 | 14,906 | 3,433 | 9,032 | ||||||||||||
| NET LOSS AND COMPREHENSIVE LOSS | $ | (47,104 | ) | $ | (94,099 | ) | $ | (28,690 | ) | $ | (25,058 | ) | ||||
| NET LOSS PER SHARE: | ||||||||||||||||
| Weighted average shares outstanding—Basic and diluted | 70,978,092 | 69,469,401 | 75,346,628 | 69,491,962 | ||||||||||||
| Basic and diluted loss per share | $ | (0.66 | ) | $ | (1.35 | ) | $ | (0.38 | ) | $ | (0.36 | ) | ||||
| LUMEXA IMAGING HOLDINGS, INC. | ||||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
| FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024 | ||||||||
| (IN THOUSANDS) | ||||||||
| (Preliminary and Unaudited) | ||||||||
| 2025 | 2024 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | (47,104 | ) | $ | (94,099 | ) | ||
| Adjustments to reconcile net loss to net cash provided by operating activities | ||||||||
| Depreciation and amortization | 40,379 | 42,164 | ||||||
| Amortization of operating lease right-of-use assets | 15,010 | 14,961 | ||||||
| Amortization of debt issuance costs | 5,739 | 6,185 | ||||||
| Amortization of cloud computing implementation costs | 439 | - | ||||||
| Write-off of debt issuance costs due to extinguishment of debt | 5,435 | 703 | ||||||
| Equity in earnings of unconsolidated affiliates | (72,135 | ) | (71,505 | ) | ||||
| Distributions from investments in unconsolidated affiliates | 64,885 | 79,531 | ||||||
| Loss on disposal of property and equipment | 968 | - | ||||||
| Gain on insurance recovery for disposed property and equipment | (1,873 | ) | - | |||||
| Gain on imaging center sold, related party | - | (2,294 | ) | |||||
| Non-cash change in fair value of interest rate caps | - | 1,274 | ||||||
| Deferred income taxes | 8,076 | 9,753 | ||||||
| Unit-based compensation | 41,604 | 56,654 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (5,896 | ) | 2,354 | |||||
| Accounts receivable, related party | 4,554 | (8,584 | ) | |||||
| Capitalized cloud computing implementation costs | (5,940 | ) | - | |||||
| Other receivables | (12,669 | ) | 907 | |||||
| Prepaid expenses | (6,277 | ) | (911 | ) | ||||
| Other assets | (7,361 | ) | (5,952 | ) | ||||
| Accounts payable | 14,415 | 2,948 | ||||||
| Accrued expenses and other current liabilities | (17,932 | ) | 12,078 | |||||
| Other liabilities | 6,133 | 7,109 | ||||||
| Operating lease liabilities | (13,376 | ) | (12,549 | ) | ||||
| Net cash provided by operating activities | 17,074 | 40,727 | ||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Proceeds from sale or disposal of property and equipment | 2,643 | 361 | ||||||
| Purchases of property and equipment | (23,477 | ) | (27,773 | ) | ||||
| Proceeds from sale of businesses | - | 3,744 | ||||||
| Proceeds from sale of business, related party | - | 1,385 | ||||||
| Contributions to investments in unconsolidated affiliates | (123 | ) | - | |||||
| Net cash used in investing activities | (20,957 | ) | (22,283 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from initial public offering, net of underwriting discounts and commissions | 434,750 | - | ||||||
| Transaction costs incurred in connection with initial public offering | (7,777 | ) | - | |||||
| Payments of long-term debt | (1,204,056 | ) | (11,845 | ) | ||||
| Proceeds from long-term debt, net of issuance costs | 827,848 | 10,608 | ||||||
| Payment of third-party debt issuance costs | (9,304 | ) | (506 | ) | ||||
| Proceeds from revolving line of credit | 5,000 | 30,000 | ||||||
| Repayments of revolving line of credit | (5,000 | ) | (30,000 | ) | ||||
| Payments of finance lease liabilities | (7,315 | ) | (11,429 | ) | ||||
| Capital contributions | 835 | 673 | ||||||
| Proceeds from accounts receivable pledging arrangement | 1,599 | - | ||||||
| Net cash provided by (used in) financing activities | 36,580 | (12,499 | ) | |||||
| NET INCREASE IN CASH AND CASH EQUIVALENTS | 32,697 | 5,945 | ||||||
| CASH AND CASH EQUIVALENTS, beginning of year | 26,131 | 20,186 | ||||||
| CASH AND CASH EQUIVALENTS, end of year | $ | 58,828 | $ | 26,131 | ||||
| LUMEXA IMAGING HOLDINGS, INC. | |||||||||||||||||
| RECONCILIATION OF GAAP TO NON-GAAP MEASURES | |||||||||||||||||
| FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2025 AND 2024 | |||||||||||||||||
| (IN THOUSANDS) | |||||||||||||||||
| (Preliminary and Unaudited) | |||||||||||||||||
| Year Ended December 31, | Quarter Ended December 31, | ||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||
| Net loss | $ | (47,104 | ) | $ | (94,099 | ) | $ | (28,690 | ) | $ | (25,058 | ) | |||||
| Depreciation and amortization | 40,379 | 42,164 | 12,395 | 9,816 | |||||||||||||
| Income tax provision | 14,885 | 14,906 | 3,433 | 9,032 | |||||||||||||
| Amortization of basis difference | 2,000 | 2,000 | 500 | 500 | |||||||||||||
| Interest expense | 118,539 | 136,027 | 28,016 | 31,387 | |||||||||||||
| Loss on extinguishment of debt | 13,453 | 703 | 13,453 | - | |||||||||||||
| Stock-based compensation | 41,604 | 56,654 | 18,572 | 14,038 | |||||||||||||
| Gain on imaging center sold, related party | - | (2,294 | ) | - | (110 | ) | |||||||||||
| Loss on disposal of property and equipment | 968 | - | 491 | - | |||||||||||||
| Other income(1) | (1,873 | ) | - | (1,873 | ) | - | |||||||||||
| Severance and executive recruiting(2) | 3,523 | 3,436 | 985 | 3,032 | |||||||||||||
| Strategic initiatives and implementation(3) | 3,459 | 5,362 | 375 | 1,946 | |||||||||||||
| Transaction costs(4) | 21,325 | 18,167 | 10,962 | 4,185 | |||||||||||||
| Litigation and settlements(5) | (113 | ) | 588 | 29 | 401 | ||||||||||||
| Other(6) | 942 | 1,904 | 56 | 469 | |||||||||||||
| Adjustments for equity in earnings | |||||||||||||||||
| of unconsolidated affiliates(7) | 18,167 | 15,321 | 5,046 | 4,106 | |||||||||||||
| Adjusted EBITDA | $ | 230,154 | $ | 200,839 | $ | 63,750 | $ | 53,744 | |||||||||
| (1) | Represents receipt of casualty insurance proceeds related to a flood at one of our centers. | ||||||||||||||||
| (2) | Includes severance and recruiting expenses for executive leadership departures as part of strategic organizational changes. | ||||||||||||||||
| (3) | Includes third-party consulting, implementation, and integration expenses incurred as part of our strategic transformation and optimization initiatives, specifically related to the deployment of a new technology system and labor model, as well as the development, customization, and integration of a new enterprise resource planning (ERP) system. | ||||||||||||||||
| (4) | Includes costs for third party non-recurring IPO costs, buy-side and sell-side due diligence activities to evaluate and execute potential mergers and acquisitions, integrate acquired businesses and one-time employee retention bonuses related to potential mergers and acquisitions. | ||||||||||||||||
| (5) | Consists of litigation and settlement costs for matters not related to core operations. | ||||||||||||||||
| (6) | Consists of other costs related to debt financing, certain de novo start-up costs related to outpatient imaging centers and certain exit costs related to closed outpatient imaging centers. | ||||||||||||||||
| (7) | To adjust for Lumexa Imaging's proportional share of depreciation and amortization, interest expense and loss on asset disposals, which are included in equity in earnings from unconsolidated affiliates. | ||||||||||||||||
| LUMEXA IMAGING HOLDINGS, INC. | ||||||||||||||||
| DETAILS OF MANAGEMENT FEE AND OTHER REVENUES | ||||||||||||||||
| FOR THE YEARS AND QUARTER ENDED DECEMBER 31, 2025 AND 2024 | ||||||||||||||||
| (IN THOUSANDS) | ||||||||||||||||
| (Preliminary and Unaudited) | ||||||||||||||||
| Year Ended December 31, | Quarter Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Components of "management fee and other revenues:" | ||||||||||||||||
| Fees for managing joint ventured outpatient sites and other third party services | $ | 86,610 | $ | 74,785 | $ | 22,113 | $ | 25,135 | ||||||||
| Zero margin pass-throughs of employee, IT and other site level costs paid by Lumexa | 133,764 | 127,234 | 35,092 | 33,064 | ||||||||||||
| Total revenues | $ | 220,374 | $ | 202,019 | $ | 57,205 | $ | 58,199 | ||||||||
